PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
2896.79%
ROE of 2896.79% while TRAW has zero. Bruce Berkowitz would confirm if minor profitability translates into a competitive edge.
-106.42%
Negative ROA while TRAW stands at 0.00%. John Neff would check for structural inefficiencies or mispriced assets.
-85.71%
Negative ROCE while TRAW is at 0.00%. Joel Greenblatt would look for capital misallocation or cyclical downturn.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.